A Standardized Protocol for Mouse Longevity Studies in Preclinical Drug Development.

Alex Zhavoronkov^1,2,3, Qian Wang⁴, Yujie Liu⁵, Wenbin Hou⁵, Yuelei Shen⁵, Dominika Wilczok^6,7, Kristen Fortney⁸, Alex Aliper², Man Zhang⁴, Feng Ren⁴, Richard A Miller⁹

¹Insilico Medicine US Inc., Cambridge, MA 02138, USA.

²Insilico Medicine AI Limited, Masdar, Abu Dhabi, United Arab Emirates.

³Insilico Medicine Hong Kong Ltd., Hong Kong SAR, China.

⁴Insilico Medicine Shanghai Ltd., Shanghai 201203, China.

⁵Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing 102609, China.

⁶Duke University, Durham, NC 27708, USA.

⁷Duke Kunshan University, Kunshan 215316, Jiangsu, China.

⁸BioAge Labs, Richmond, CA 94804, USA.

⁹Department of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, MI 48109-5796, USA.

PubMed PMC DOI PDF

Abstract

Although aging is increasingly recognized as a key factor in chronic disease management, preclinical drug development rarely incorporates direct assessments of lifespan. To date, no biotechnology company has conducted a full mouse lifespan study for a therapeutic agent prior to human clinical trials, despite widespread chronic use of many approved drugs. This oversight stems from a lack of standar…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.